Dynaris: We set new standard in oxygen therapy; 7 patents, FDA, superior therapy, & more

1

FDA 510 (K), EUA, ISO-13485 Quality System, FDA registered manufacturing in-house, Ready to go!

2

5.9 million patients on oxygen in the U.S. alone growing to over 7 million patients in 2023.

3

Protected by 7 U.S. Patents, more pending, foreign patents pending.

4

Experienced team with a history of success, from concept through acquisition. CEO has 28 patents

5

Superior oxygen therapy for patients. Sets a new therapeutic standard for oxygen patients.

6

Oxygen therapies are expanding to other areas; i.e. cluster headaches and wound healing treatments

7

Additional products in development expand our technologies into other therapeutic market segments.

The founders have been face-to-face with patients in the respiratory business for more than the last 4 decades. We've seen their pain and suffering. We have seized the opportunity to greatly help them and set a new standard in oxygen therapy. Quite simply, patients ask us to help them. They're family!

Dynaris

We set new standard in oxygen therapy; 7 patents, FDA, superior therapy, & more

$179,980

Highlights

Featured Investor

Our Team

Pitch

Downloads